Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 392

1.

A new hepatoma cell line exhibiting high susceptibility to hepatitis B virus infection.

Ueda Y, Gu W, Dansako H, Nishitsuji H, Satoh S, Shimotohno K, Kato N.

Biochem Biophys Res Commun. 2019 Jul 12;515(1):156-162. doi: 10.1016/j.bbrc.2019.05.126. Epub 2019 May 24.

PMID:
31133379
2.

Apolipoprotein E is an HIV-1-inducible inhibitor of viral production and infectivity in macrophages.

Siddiqui R, Suzu S, Ueno M, Nasser H, Koba R, Bhuyan F, Noyori O, Hamidi S, Sheng G, Yasuda-Inoue M, Hishiki T, Sukegawa S, Miyagi E, Strebel K, Matsushita S, Shimotohno K, Ariumi Y.

PLoS Pathog. 2018 Nov 29;14(11):e1007372. doi: 10.1371/journal.ppat.1007372. eCollection 2018 Nov.

3.

Circulating microRNA-636 is associated with the elimination of hepatitis C virus by ombitasvir/paritaprevir/ritonavir.

Morishita A, Yoneyama H, Iwama H, Fujita K, Watanabe M, Hirose K, Tadokoro T, Oura K, Sakamoto T, Mimura S, Nomura T, Oryu M, Himoto T, Shimotohno K, Masaki T.

Oncotarget. 2018 Aug 10;9(62):32054-32062. doi: 10.18632/oncotarget.25889. eCollection 2018 Aug 10.

4.

Multiple antiviral activities of the antimalarial and anti-hepatitis C drug candidates N-89 and N-251.

Ueda Y, Gu W, Dansako H, Kim HS, Yoshizaki S, Okumura N, Ishikawa T, Nishitsuji H, Kato F, Hishiki T, Satoh S, Ishii K, Masuda M, Shimotohno K, Ikeda M, Kato N.

Biochem Biophys Rep. 2018 Jun 1;15:1-6. doi: 10.1016/j.bbrep.2018.05.007. eCollection 2018 Sep.

5.

Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients.

Fujita K, Mimura S, Iwama H, Nakahara M, Oura K, Tadokoro T, Nomura T, Tani J, Yoneyama H, Morishita A, Oryu M, Himoto T, Nishitsuji H, Shimotohno K, Omata M, Masaki T.

Int J Mol Sci. 2018 Jul 2;19(7). pii: E1940. doi: 10.3390/ijms19071940.

6.

Development of a cell-based assay to identify hepatitis B virus entry inhibitors targeting the sodium taurocholate cotransporting polypeptide.

Miyakawa K, Matsunaga S, Yamaoka Y, Dairaku M, Fukano K, Kimura H, Chimuro T, Nishitsuji H, Watashi K, Shimotohno K, Wakita T, Ryo A.

Oncotarget. 2018 May 4;9(34):23681-23694. doi: 10.18632/oncotarget.25348. eCollection 2018 May 4.

7.

TIP60 Complex Inhibits Hepatitis B Virus Transcription.

Nishitsuji H, Ujino S, Harada K, Shimotohno K.

J Virol. 2018 Feb 26;92(6). pii: e01788-17. doi: 10.1128/JVI.01788-17. Print 2018 Mar 15.

8.

Investigating the hepatitis B virus life cycle using engineered reporter hepatitis B viruses.

Nishitsuji H, Harada K, Ujino S, Zhang J, Kohara M, Sugiyama M, Mizokami M, Shimotohno K.

Cancer Sci. 2018 Jan;109(1):241-249. doi: 10.1111/cas.13440. Epub 2017 Dec 7.

9.

Molecular characterization of AID-mediated reduction of hepatitis B virus transcripts.

Que L, Liu G, Kitamura K, Wakae K, Li Y, Nishitsuji H, Ujino S, Shimotohno K, Muramatsu M.

Virology. 2017 Oct;510:281-288. doi: 10.1016/j.virol.2017.07.035. Epub 2017 Aug 2.

10.

Identification of KX2-391 as an inhibitor of HBV transcription by a recombinant HBV-based screening assay.

Harada K, Nishitsuji H, Ujino S, Shimotohno K.

Antiviral Res. 2017 Aug;144:138-146. doi: 10.1016/j.antiviral.2017.06.005. Epub 2017 Jun 15.

PMID:
28624460
11.

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle.

Nishitsuji H, Yamamoto H, Shiina R, Harada K, Ujino S, Shimotohno K.

J Vis Exp. 2017 Feb 1;(120). doi: 10.3791/54849.

12.

Long noncoding RNA #32 contributes to antiviral responses by controlling interferon-stimulated gene expression.

Nishitsuji H, Ujino S, Yoshio S, Sugiyama M, Mizokami M, Kanto T, Shimotohno K.

Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):10388-93. doi: 10.1073/pnas.1525022113. Epub 2016 Aug 31.

13.

Human induced pluripotent stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus.

Kaneko S, Kakinuma S, Asahina Y, Kamiya A, Miyoshi M, Tsunoda T, Nitta S, Asano Y, Nagata H, Otani S, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Nakauchi H, Nishitsuji H, Ujino S, Shimotohno K, Iwamoto M, Watashi K, Wakita T, Watanabe M.

Sci Rep. 2016 Jul 8;6:29358. doi: 10.1038/srep29358.

14.

Hepatitis C virus utilizes VLDLR as a novel entry pathway.

Ujino S, Nishitsuji H, Hishiki T, Sugiyama K, Takaku H, Shimotohno K.

Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):188-93. doi: 10.1073/pnas.1506524113. Epub 2015 Dec 23. Erratum in: Nat Rev Gastroenterol Hepatol. 2016 Apr;13(4):188.

15.

Novel reporter system to monitor early stages of the hepatitis B virus life cycle.

Nishitsuji H, Ujino S, Shimizu Y, Harada K, Zhang J, Sugiyama M, Mizokami M, Shimotohno K.

Cancer Sci. 2015 Nov;106(11):1616-24. doi: 10.1111/cas.12799. Epub 2015 Oct 16.

16.

Apolipoprotein E, but Not Apolipoprotein B, Is Essential for Efficient Cell-to-Cell Transmission of Hepatitis C Virus.

Gondar V, Molina-Jiménez F, Hishiki T, García-Buey L, Koutsoudakis G, Shimotohno K, Benedicto I, Majano PL.

J Virol. 2015 Oct;89(19):9962-73. doi: 10.1128/JVI.00577-15. Epub 2015 Jul 22.

17.

A new role for PGA1 in inhibiting hepatitis C virus-IRES-mediated translation by targeting viral translation factors.

Tsukimoto A, Sugiyama R, Abe M, Nishitsuji H, Shimizu Y, Shimotohno K, Kawai G, Takaku H.

Antiviral Res. 2015 May;117:1-9. doi: 10.1016/j.antiviral.2015.01.013. Epub 2015 Feb 7.

PMID:
25666760
18.

Murine Herc6 Plays a Critical Role in Protein ISGylation In Vivo and Has an ISGylation-Independent Function in Seminal Vesicles.

Arimoto K, Hishiki T, Kiyonari H, Abe T, Cheng C, Yan M, Fan JB, Futakuchi M, Tsuda H, Murakami Y, Suzuki H, Zhang DE, Shimotohno K.

J Interferon Cytokine Res. 2015 May;35(5):351-8. doi: 10.1089/jir.2014.0113. Epub 2014 Nov 19.

19.

Hepatitis C virus NS5A protein enhances gluconeogenesis through upregulation of Akt-/JNK-PEPCK signalling pathways.

Kuo YC, Chen IY, Chang SC, Wu SC, Hung TM, Lee PH, Shimotohno K, Chang MF.

Liver Int. 2014 Oct;34(9):1358-68.

PMID:
25360475
20.

The RNA-editing enzyme APOBEC1 requires heterogeneous nuclear ribonucleoprotein Q isoform 6 for efficient interaction with interleukin-8 mRNA.

Shimizu Y, Nishitsuji H, Marusawa H, Ujino S, Takaku H, Shimotohno K.

J Biol Chem. 2014 Sep 19;289(38):26226-38. doi: 10.1074/jbc.M114.563221. Epub 2014 Aug 6.

21.

The J6JFH1 strain of hepatitis C virus infects human B-cells with low replication efficacy.

Nakai M, Seya T, Matsumoto M, Shimotohno K, Sakamoto N, Aly HH.

Viral Immunol. 2014 Aug;27(6):285-94. doi: 10.1089/vim.2013.0140. Epub 2014 May 22.

PMID:
24853207
22.

Interferon-mediated ISG15 conjugation restricts dengue virus 2 replication.

Hishiki T, Han Q, Arimoto K, Shimotohno K, Igarashi T, Vasudevan SG, Suzuki Y, Yamamoto N.

Biochem Biophys Res Commun. 2014 May 23;448(1):95-100. doi: 10.1016/j.bbrc.2014.04.081. Epub 2014 Apr 21.

PMID:
24769207
23.

Critical role of interferon-α constitutively produced in human hepatocytes in response to RNA virus infection.

Tsugawa Y, Kato H, Fujita T, Shimotohno K, Hijikata M.

PLoS One. 2014 Feb 26;9(2):e89869. doi: 10.1371/journal.pone.0089869. eCollection 2014.

24.

Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers.

Abe Y, Aly HH, Hiraga N, Imamura M, Wakita T, Shimotohno K, Chayama K, Hijikata M.

Gastroenterology. 2013 Sep;145(3):658-67.e11. doi: 10.1053/j.gastro.2013.05.014. Epub 2013 May 16.

PMID:
23684750
25.

Hepatitis C virus infection induces inflammatory cytokines and chemokines mediated by the cross talk between hepatocytes and stellate cells.

Nishitsuji H, Funami K, Shimizu Y, Ujino S, Sugiyama K, Seya T, Takaku H, Shimotohno K.

J Virol. 2013 Jul;87(14):8169-78. doi: 10.1128/JVI.00974-13. Epub 2013 May 15.

26.

PML tumor suppressor protein is required for HCV production.

Kuroki M, Ariumi Y, Hijikata M, Ikeda M, Dansako H, Wakita T, Shimotohno K, Kato N.

Biochem Biophys Res Commun. 2013 Jan 11;430(2):592-7. doi: 10.1016/j.bbrc.2012.11.108. Epub 2012 Dec 5.

27.

Different mechanisms of hepatitis C virus RNA polymerase activation by cyclophilin A and B in vitro.

Weng L, Tian X, Gao Y, Watashi K, Shimotohno K, Wakita T, Kohara M, Toyoda T.

Biochim Biophys Acta. 2012 Dec;1820(12):1886-92. doi: 10.1016/j.bbagen.2012.08.017. Epub 2012 Aug 28.

PMID:
22954804
28.

Self-enhancement of hepatitis C virus replication by promotion of specific sphingolipid biosynthesis.

Hirata Y, Ikeda K, Sudoh M, Tokunaga Y, Suzuki A, Weng L, Ohta M, Tobita Y, Okano K, Ozeki K, Kawasaki K, Tsukuda T, Katsume A, Aoki Y, Umehara T, Sekiguchi S, Toyoda T, Shimotohno K, Soga T, Nishijima M, Taguchi R, Kohara M.

PLoS Pathog. 2012;8(8):e1002860. doi: 10.1371/journal.ppat.1002860. Epub 2012 Aug 16.

29.

Lipoprotein component associated with hepatitis C virus is essential for virus infectivity.

Shimizu Y, Hishiki T, Ujino S, Sugiyama K, Funami K, Shimotohno K.

Curr Opin Virol. 2011 Jul;1(1):19-26. doi: 10.1016/j.coviro.2011.05.017. Epub 2011 Jun 12. Review.

PMID:
22440563
30.

Detergent-induced activation of the hepatitis C virus genotype 1b RNA polymerase.

Weng L, Kohara M, Wakita T, Shimotohno K, Toyoda T.

Gene. 2012 Apr 1;496(2):79-87. doi: 10.1016/j.gene.2012.01.044. Epub 2012 Jan 28.

PMID:
22306265
31.

In vitro models for analysis of the hepatitis C virus life cycle.

Aly HH, Shimotohno K, Hijikata M, Seya T.

Microbiol Immunol. 2012 Jan;56(1):1-9. doi: 10.1111/j.1348-0421.2011.00403.x. Review.

32.

The interaction between human initiation factor eIF3 subunit c and heat-shock protein 90: a necessary factor for translation mediated by the hepatitis C virus internal ribosome entry site.

Ujino S, Nishitsuji H, Sugiyama R, Suzuki H, Hishiki T, Sugiyama K, Shimotohno K, Takaku H.

Virus Res. 2012 Jan;163(1):390-5. doi: 10.1016/j.virusres.2011.10.003. Epub 2011 Oct 14.

PMID:
22016036
33.

Molecular basis for the actions of Hsp90 inhibitors and cancer therapy.

Yamaki H, Nakajima M, Shimotohno KW, Tanaka N.

J Antibiot (Tokyo). 2011 Sep;64(9):635-44. doi: 10.1038/ja.2011.60. Epub 2011 Aug 3. Review.

PMID:
21811259
34.

Development of mouse hepatocyte lines permissive for hepatitis C virus (HCV).

Aly HH, Oshiumi H, Shime H, Matsumoto M, Wakita T, Shimotohno K, Seya T.

PLoS One. 2011;6(6):e21284. doi: 10.1371/journal.pone.0021284. Epub 2011 Jun 22.

35.

Will there be an HCV meeting in 2020? Summary of the 17th international meeting on hepatitis C virus and related viruses.

Wakita T, Suzuki T, Evans MJ, Shimotohno K, Chayama K, Matsuura Y, Hijikata M, Moriishi K, Seya T, Enomoto N, Koike K, Kato N, Kanto T, Hotta H.

Gastroenterology. 2011 Jul;141(1):e1-5. doi: 10.1053/j.gastro.2011.05.027. Epub 2011 May 24. No abstract available.

PMID:
21620847
36.

Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C.

Onomoto K, Morimoto S, Kawaguchi T, Toyoda H, Tanaka M, Kuroda M, Uno K, Kumada T, Matsuda F, Shimotohno K, Fujita T, Murakami Y.

PLoS One. 2011;6(5):e19799. doi: 10.1371/journal.pone.0019799. Epub 2011 May 13.

37.

Cyclosporin A associated helicase-like protein facilitates the association of hepatitis C virus RNA polymerase with its cellular cyclophilin B.

Morohashi K, Sahara H, Watashi K, Iwabata K, Sunoki T, Kuramochi K, Takakusagi K, Miyashita H, Sato N, Tanabe A, Shimotohno K, Kobayashi S, Sakaguchi K, Sugawara F.

PLoS One. 2011 Apr 29;6(4):e18285. doi: 10.1371/journal.pone.0018285.

38.

The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families.

Murakami Y, Toyoda H, Tanaka M, Kuroda M, Harada Y, Matsuda F, Tajima A, Kosaka N, Ochiya T, Shimotohno K.

PLoS One. 2011 Jan 24;6(1):e16081. doi: 10.1371/journal.pone.0016081.

39.

Hepatitis C virus core protein abrogates the DDX3 function that enhances IPS-1-mediated IFN-beta induction.

Oshiumi H, Ikeda M, Matsumoto M, Watanabe A, Takeuchi O, Akira S, Kato N, Shimotohno K, Seya T.

PLoS One. 2010 Dec 8;5(12):e14258. doi: 10.1371/journal.pone.0014258.

40.

Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C.

Murakami Y, Tanaka M, Toyoda H, Hayashi K, Kuroda M, Tajima A, Shimotohno K.

BMC Med Genomics. 2010 Oct 22;3:48. doi: 10.1186/1755-8794-3-48.

41.

Sphingomyelin activates hepatitis C virus RNA polymerase in a genotype-specific manner.

Weng L, Hirata Y, Arai M, Kohara M, Wakita T, Watashi K, Shimotohno K, He Y, Zhong J, Toyoda T.

J Virol. 2010 Nov;84(22):11761-70. doi: 10.1128/JVI.00638-10. Epub 2010 Sep 15.

42.

Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms.

Hishiki T, Shimizu Y, Tobita R, Sugiyama K, Ogawa K, Funami K, Ohsaki Y, Fujimoto T, Takaku H, Wakita T, Baumert TF, Miyanari Y, Shimotohno K.

J Virol. 2010 Nov;84(22):12048-57. doi: 10.1128/JVI.01063-10. Epub 2010 Sep 8.

43.

Lipoprotein lipase and hepatic triglyceride lipase reduce the infectivity of hepatitis C virus (HCV) through their catalytic activities on HCV-associated lipoproteins.

Shimizu Y, Hishiki T, Sugiyama K, Ogawa K, Funami K, Kato A, Ohsaki Y, Fujimoto T, Takaku H, Shimotohno K.

Virology. 2010 Nov 10;407(1):152-9. doi: 10.1016/j.virol.2010.08.011. Epub 2010 Sep 6.

44.

Polyubiquitin conjugation to NEMO by triparite motif protein 23 (TRIM23) is critical in antiviral defense.

Arimoto K, Funami K, Saeki Y, Tanaka K, Okawa K, Takeuchi O, Akira S, Murakami Y, Shimotohno K.

Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15856-61. doi: 10.1073/pnas.1004621107. Epub 2010 Aug 19.

45.

HTLV-1 basic leucine-zipper factor, HBZ, interacts with MafB and suppresses transcription through a Maf recognition element.

Ohshima T, Mukai R, Nakahara N, Matsumoto J, Isono O, Kobayashi Y, Takahashi S, Shimotohno K.

J Cell Biochem. 2010 Sep 1;111(1):187-94. doi: 10.1002/jcb.22687.

PMID:
20506502
46.

Inhibition of septation in Bacillus subtilis by a peptide antibiotic, edeine B(1).

Shimotohno KW, Kawamura F, Natori Y, Nanamiya H, Magae J, Ogata H, Endo T, Suzuki T, Yamaki H.

Biol Pharm Bull. 2010;33(4):568-71.

47.

Combination therapy for hepatitis C virus with heat-shock protein 90 inhibitor 17-AAG and proteasome inhibitor MG132.

Ujino S, Yamaguchi S, Shimotohno K, Takaku H.

Antivir Chem Chemother. 2010 Mar 9;20(4):161-7. doi: 10.3851/IMP1479.

PMID:
20231781
48.

Anti-bovine viral diarrhoea virus and hepatitis C virus activity of the cyclooxygenase inhibitor SC-560.

Okamoto M, Sakai M, Goto Y, Salim MT, Baba C, Goto K, Watashi K, Shimotohno K, Baba M.

Antivir Chem Chemother. 2009 Sep 25;20(1):47-54. doi: 10.3851/IMP1372.

PMID:
19794231
49.

Synthesis and anti-HCV activity of 2',5'-deoxy-5'-phenacyladenosine analogs.

Ikejiri M, Ohshima T, Fukushima A, Shimotohno K, Maruyama T.

Nucleic Acids Symp Ser (Oxf). 2009;(53):103-4. doi: 10.1093/nass/nrp052.

PMID:
19749281
50.

Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor.

Goto K, Watashi K, Inoue D, Hijikata M, Shimotohno K.

Cancer Sci. 2009 Oct;100(10):1943-50. doi: 10.1111/j.1349-7006.2009.01263.x. Epub 2009 Jun 26.

Supplemental Content

Loading ...
Support Center